PIKfyve

PIKfyve製品

  • All (5)
  • PIKfyve阻害剤 (5)
  • 新製品
製品コード 製品名称 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
S1219 YM201636 YM201636 is a selective PIKfyve inhibitor with IC50 of 33 nM, less potent to p110α and insensitive to Fabl (yeast orthologue). YM-201636 suppresses the growth of liver cancer via the induction of autophagy.
Mol Biol Cell, 2024, 35(5):ar70
Nat Commun, 2022, 13(1):2136
Blood Cancer J, 2022, 12(3):39
S6414 Apilimod Apilimod is a potent and orally-available inhibitor of the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23) with the potential to treat certain autoimmune and inflammatory diseases. Apilimod (STA-5326) inhibits IL-12 with IC50 of 1 nM, 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs, human monocytes and mouse PBMCs, respectively. Apilimod (STA-5326) is also a cell permeable small molecule that specifically inhibits PIKfyve with IC50 of 14 nM.
Cells, 2024, 13(11)953
bioRxiv, 2024, 2024.02.28.582543
bioRxiv, 2024, 2024.04.15.589676
S6912 Vacuolin-1 Vacuolin-1 is a potent and cell-permeable inhibitor that blocks the Ca(2+)-dependent exocytosis of lysosomes and prevents the release of lysosomal content without affecting the process of resealing. Vacuolin-1 is also a potent and selective PIKfyve inhibitor, and inhibits autophagy by impairing lysosomal maturation via PIKfyve inhibition.
Virulence, 2024, 15(1):2350893
Virulence, 2024, 15(1):2350893
Nat Commun, 2023, 14(1):3997
S0785 Apilimod mesylate Apilimod mesylate is a potent and orally-available inhibitor of the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23) with the potential to treat certain autoimmune and inflammatory diseases. Apilimod mesylate (STA-5326 mesylate) inhibits IL-12 with IC50 of 1 nM, 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs, human monocytes and mouse PBMCs, respectively. Apilimod mesylate (STA-5326 mesylate) is also a cell permeable small molecule that specifically inhibits PIKfyve with IC50 of 14 nM.
bioRxiv, 2024, 2024.02.28.582543
Stem Cell Reports, 2022, 17(2):397-412
Hum Mol Genet, 2021, 29(22):3589-3605
E2933 MOMIPP MOMIPP, a macropinocytosis inducer, is a PIKfyve inhibitor. MOMIPP readily penetrates the blood-brain barrier and is moderately effective in suppressing progression of intracerebral glioblastoma xenografts.
S1219 YM201636 YM201636 is a selective PIKfyve inhibitor with IC50 of 33 nM, less potent to p110α and insensitive to Fabl (yeast orthologue). YM-201636 suppresses the growth of liver cancer via the induction of autophagy.
Mol Biol Cell, 2024, 35(5):ar70
Nat Commun, 2022, 13(1):2136
Blood Cancer J, 2022, 12(3):39
S6414 Apilimod Apilimod is a potent and orally-available inhibitor of the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23) with the potential to treat certain autoimmune and inflammatory diseases. Apilimod (STA-5326) inhibits IL-12 with IC50 of 1 nM, 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs, human monocytes and mouse PBMCs, respectively. Apilimod (STA-5326) is also a cell permeable small molecule that specifically inhibits PIKfyve with IC50 of 14 nM.
Cells, 2024, 13(11)953
bioRxiv, 2024, 2024.02.28.582543
bioRxiv, 2024, 2024.04.15.589676
S6912 Vacuolin-1 Vacuolin-1 is a potent and cell-permeable inhibitor that blocks the Ca(2+)-dependent exocytosis of lysosomes and prevents the release of lysosomal content without affecting the process of resealing. Vacuolin-1 is also a potent and selective PIKfyve inhibitor, and inhibits autophagy by impairing lysosomal maturation via PIKfyve inhibition.
Virulence, 2024, 15(1):2350893
Virulence, 2024, 15(1):2350893
Nat Commun, 2023, 14(1):3997
S0785 Apilimod mesylate Apilimod mesylate is a potent and orally-available inhibitor of the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23) with the potential to treat certain autoimmune and inflammatory diseases. Apilimod mesylate (STA-5326 mesylate) inhibits IL-12 with IC50 of 1 nM, 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs, human monocytes and mouse PBMCs, respectively. Apilimod mesylate (STA-5326 mesylate) is also a cell permeable small molecule that specifically inhibits PIKfyve with IC50 of 14 nM.
bioRxiv, 2024, 2024.02.28.582543
Stem Cell Reports, 2022, 17(2):397-412
Hum Mol Genet, 2021, 29(22):3589-3605
E2933 MOMIPP MOMIPP, a macropinocytosis inducer, is a PIKfyve inhibitor. MOMIPP readily penetrates the blood-brain barrier and is moderately effective in suppressing progression of intracerebral glioblastoma xenografts.

PIKfyve阻害剤の選択性比較

Tags: PIKfyve Inhibitor | PIKfyve modulator | PIKfyve Review